

ITOG Quarterly Update E-Newsletter



Board of Directors

Naifa Busaidy, MD

MD Anderson Cancer Center

Andrew Gianoukakis MD,

University of California Los Angeles - Hospital: Harbor

Elizabeth Grubbs, MD

MD Anderson Cancer Center

Alan Ho MD, PhD,

Memorial Sloan-Kettering

Yariv Houvras, MD

Weill Cornell Medical Center

Executive Committee

Manisha H. Shah MD, Chair

The Ohio State University

Sareh Parangi MD, Secretary

Harvard Medical School

Eric Sherman MD Chair, Protocol Committee

Memorial Sloan-Kettering Cancer Center

Dwight Vicks III MBA, CFO & Co-Founder

President, Vicks, Inc.

Sophie Leboulleux, MD

Institut Gustave Roussy

Kate Newbold, MD

The Royal Marsden NHS

Gregory Randolph, MD

Massachusetts Eye and Ear

Mabel Ryder, MD

Mayo Clinic (Rochester)

Julie Ann Sosa MD,

University of California - San Francisco

Christine Spitzweg, MD

University Hospital Munich, Ludwig-Maximilians



Message from the Chair

Manisha Shah, MD

Dear Friends, as we have entered into the autumn season, I hope that you and your loved ones are able to take some time off to soak in incredible beauty of the magical show that nature puts out! I trust that you and your families are safe during COVID-19 pandemic.

At the ITOG leadership, we are feeling new energy with great addition of Drs. Yariv Houvras, Kate Newbold, Mabel Ryder and Christine Spitzweg to the Board of Directors (BOD) team and I thank each of you for your participation to that election. I am proud to witness a milestone at ITOG leadership where >50% of the BOD are women. I am also happy to see increased international representation at the BOD. With help of this excellent and diverse leadership team, I am committed to make progress in right direction to achieve mission of ITOG.

Talking about the mission, we have some exciting news for clinical trials. Please join me in congratulating Dr. Bryan Haugen and team for presenting results of investigator-initiated ITOG-ACCRU 1504 clinical trial at the *European Society for Medical Oncology (ESMO) Annual Virtual Congress 2020*. Furthermore, we have enrolled the first patient to recently opened clinical trial (OSU 17277) for patients with BRAF mutated anaplastic and poorly differentiated thyroid Cancer. Also, do not miss the news on a new initiative ITOG is taking to build and support thyroid cancer registry. Finally, I would like to thank you in advance for taking time to nominate for an election to choose our next leader—now called 'president' for ITOG.

[ITOG Active Clinical Trials](#)

[A Phase I Trial Of Concurrent Intensity Modulated Radiation Therapy \(IMRT\) And Dabrafenib/Trametinib In BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer](#)

Accrual Status: Accruing,

PI: Manisha Shah, MD, Ohio State University

[Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab \(CaboNivolpi\) for Advanced Differentiated Thyroid Cancer](#)

Accrual Status: Accruing

PI: Bhavana Konda, MD, MPH. Ohio State University

[Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer\(LIBRETTO- 001\)](#)

Accrual Status: Accruing limited cohorts

PI: Lori Wirth, MD Massachusetts General Hospital

[ACCRU/ITOG 1504 Combination immunotherapy with Multikinase Inhibitor \(MKI\) in Progressive, Radiodineresistant Differentiated Thyroid Cancers](#)

Accrual Status: Closed to Accrual

Accrual Goal: 60 Current Accrual: 60

PI: Bryan Haugen, MD University of Colorado Cancer Center

Selumetinib Rius RAI for RAI-Avid Thyroid Cancers

Accrual Status: Closed to Accrual

Accrual Goal: 60 Current Accrual: 60

PI: Alan Ho, MD, Memorial Sloan-Kettering Cancer Center

ITOG TOP NEWS

ITOG's Collaborative Research Leading to Major Breakthrough in Treatment of Thyroid Cancer

It is with great pleasure to share that Dr. Lori Wirth, Dr. Eric Sherman, Dr. Bruce Robinson et al. (NEJM, Aug 27 2020) found that a phase 1-2 trial of selpercatinib, a selective RET-inhibitor, showed evident and durable efficacy in the treatment of patients with RET-altered thyroid cancer...[More](#)

Call for Nominations for the ITOG President (Chair) Now Open!

The Term of Chair (President) of the Board of Directors is three (3) years May 2021 – May 2024.

Candidate must meet all following criteria

1. ITOG Member in good standing
2. Interested in and committed to advancing the Mission of ITOG
3. A current or past ITOG Board of Directors (List on following page)

Nominations Close Midnight, Sunday October 25, 2020

[Click Here For More Information](#)

ITOG BOD votes to move forward with Tumor Registry Partnership

The Board of Directors has chosen, as an initial effort, to work with the Medullary Thyroid Cancer (MTC) Registry managed by two of its member institutions, ...[More](#)

Dr. Robert Gagel Receives Jean Vicks Inspiration Award

During the ITOG General Membership meeting on July 30th, 2020, the Board of Directors was pleased to present Dr. Robert Gagel with the Jean Vicks Inspiration Award for his significant contributions to thyroid cancer research ...[More](#)

ITOG Welcomes New Board of Director Members

Terms 2020 - 2023

- Andrew Gianoukakis, MD - Re-elected for new 3 year term
- Yariv Houvras, MD
- Kate Newbold, MD
- Mabel Ryder, MD
- Christine Spitzweg, MD

[Click here for more information](#)

Check out the ITOG Leadership Organizational Chart and Demographics!

ITOG Leadership Org Chart and
Demographics

ITOG Bylaws Updated

1. Change title from ITOG Chair to President (Article III, Section 2)
2. Update eligibility for President will require either prior or current Board experience (Article III, Section 2)
3. Updated Language regarding appointment of CFO, advisory member, secretary, and committee makeup, by the President and approved by Board of Directors (Article III, Section 1)

[Click here for Bylaws](#)

Membership Corner

Have You Updated your ITOG Membership Profile?

As a member, you will find access to our Member Directory, Community Forum, and Members Only information, including ITOG Clinical Trial Updates.

ITOG Members are making an impact on our mission to "Catalyze a Cure for Thyroid Cancer" and you can read about them here.

- **Paying your Membership**
- **Making a Donation?**
- **Credit Cards Now Accepted Online**

We are proud to announce that ITOG website now accepts credit cards in addition to PayPal for membership dues and donations

Get Social!

Stay connected with ITOG on social media! Follow us on [Twitter](#) and [Instagram](#) and connect on [LinkedIn](#) for the latest news and updates. If you have a story to share, please email relevant links and photos to judy.dallas@osumc.edu.



@@unsubscribe_url@@